STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world

Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11

(2019) Linnéa La Fleur et al.   LUNG CANCER

Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers

(2019) Carminia Maria Della Corte et al.   Cancer Discovery

Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer

(2019) Sandra D. Griffith et al.   ADVANCES IN THERAPY

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database

(2019) Gaurav Singal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

(2019) Ferdinandos Skoulidis et al.   JOURNAL OF CLINICAL ONCOLOGY

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

(2019) Matthias Scheffler et al.   Journal of Thoracic Oncology

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

(2019) Howard West et al.   LANCET ONCOLOGY

Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer

(2019) Kathryn C. Arbour et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial

(2019) N. Rizvi et al.   Journal of Thoracic Oncology

PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy

(2018) Tricia R. Cottrell et al.   CANCER JOURNAL

PD-1 blockade in advanced NSCLC: A focus on pembrolizumab

(2018) Solange Peters et al.   CANCER TREATMENT REVIEWS

TP53,STK11andEGFRMutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma

(2018) Jerome Biton et al.   CLINICAL CANCER RESEARCH

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

(2018) Marina Chiara Garassino et al.   LANCET ONCOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

Somatic STK11/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC.

(2018) Maria Jure-Kunkel et al.   JOURNAL OF CLINICAL ONCOLOGY

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

(2018) David R. Gandara et al.   NATURE MEDICINE

2OSomatic mutations in BRCA2, NFE2L2, ARID1A and NOTCH1 sensitize to anti-PDL1 therapy in multiple tumor types

(2018) M Kuziora et al.   ANNALS OF ONCOLOGY

LBA55Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

(2018) E S Kim et al.   ANNALS OF ONCOLOGY

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer

(2018) Shunsuke Kitajima et al.   Cancer Discovery

Real-world Data for Clinical Evidence Generation in Oncology

(2017) Sean Khozin et al.   JNCI-Journal of the National Cancer Institute

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value

(2017) Francesco Facchinetti et al.   LUNG CANCER

Real-world Data for Clinical Evidence Generation in Oncology

(2017) Sean Khozin et al.   JNCI-Journal of the National Cancer Institute

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

(2016) S. Koyama et al.   CANCER RESEARCH

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

(2012) Marcin Imielinski et al.   CELL

Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program

(2011) Karynsa Cetin et al.   Clinical Epidemiology